DeneB Clásico S

Clinical Monograph: DeneB Classic-S (Hyaluronic Acid 20 mg/mL with Lidocaine)

1. Classification and Chemical Overview

• Active Composition: Cross-linked sodium hyaluronate at a concentration of 20 mg/mL, combined with 0.3% (3 mg/mL) lidocaine for local anesthetic comfort during injection.

• Proprietary Technology: Manufactured using advanced multi-stage cross-linking (such as MDM / Micro-bead Monophasic technology), which optimizes structural cohesivity, minimizes residual cross-linking agents (BDDE), and provides a smooth, moldable gel matrix.

• Therapeutic Class: Mid-to-deep dermal / subcutaneous soft-tissue augmentation device / Hyaluronic acid filler.

• Regulatory Status: Professional-use medical device requiring administration exclusively by trained medical or aesthetic practitioners.

2. Mechanism of Action and Pharmacodynamics

• Balanced Viscoelasticity & Support: DeneB Classic-S bridges the gap between fine-line correctors and heavy volumetric agents, offering optimal elasticity and lifting capacity to smooth deeper wrinkles and contour defined facial or bodily features.

• Cohesivity & Gel Stability: The micro-bead monophasic structure resists rapid enzymatic degradation and compression, ensuring the product maintains its molded shape and stays localized within the target tissue plane.

• Hydration & Integration: The hydrophilic hyaluronic acid matrix binds water molecules within the extracellular matrix to enhance localized tissue hydration and support structural skin quality.

3. Approved Clinical Indications and Dosing Scope

• Indications:

  • Correction of moderate-to-deep facial wrinkles, nasolabial folds, and marionette lines.

  • Contouring and shaping of specific facial features (such as the chin, jawline, or cheeks) or targeted body areas requiring medium-depth volume.

• Administration & Depth:

  • Supplied in a 10 mL pre-filled sterile syringe (or standardized multi-pack format depending on regional distribution).

  • Injected precisely into the mid-to-deep dermis or subcutaneous layer using appropriate sterile tunneling, linear threading, or depot techniques.

• Duration of Effect: Typically persists between 12 to 18 months, influenced by the patient’s metabolic rate, injection site, and lifestyle factors.

4. Pharmacokinetic Profile

• Tissue Retention: The cross-linked network provides elevated resistance to endogenous hyaluronidase breakdown, ensuring extended residency compared to non-modified hyaluronan formulations.

• Metabolism: Progressively degraded via normal physiological pathways into non-toxic monomers (glucuronic acid and N-acetylglucosamine), ultimately breaking down into water and carbon dioxide.

5. Physiological Effects and Adverse Event Spectrum

Local tissue responses reflect standard mechanical needle insertion and acute soft-tissue adjustment.

Adverse Reaction Profile

• Common ($\ge 1/100$ to $<1/10$): Transient injection site reactions including localized erythema, swelling, pain, tenderness, bruising, and firmness.

• Uncommon ($\ge 1/1,000$ to $<1/100$): Temporary palpable nodules, localized asymmetry, or minor contour irregularities.

• Rare / Severe (<1/1,000): Deep tissue infection, sterile abscess formation, delayed hypersensitivity reactions, or vascular compromise secondary to inadvertent intravascular placement.

6. Contraindications, Drug Interactions, and Clinical Precautions

Contraindicaciones

• Known hypersensitivity to hyaluronic acid or amide-type local anesthetics (lidocaine).

• Active cutaneous infections, inflammatory skin conditions, or open lesions at the target site.

• History of severe systemic allergies, anaphylaxis, or predisposition to hypertrophic scarring or keloids.

• Pregnancy and breastfeeding.

Key Interacting Factors & Warnings

• Vascular Safety: Clinicians must possess thorough anatomical knowledge, utilize aspiration techniques, and apply controlled extrusion force to avoid accidental intravascular injection.

• Aseptic Handling: The syringe is intended for single-patient use only and must be handled under strict aseptic conditions.

Clinical Precautions and Post-Treatment Guidelines

• Post-Procedure Care: Advise patients to avoid heavy pressure, intense friction, extreme temperatures (such as saunas, steam rooms, or intense UV exposure), and strenuous physical exercise or athletic strain for at least 1 to 2 weeks post-injection.